Refractory reflux disease. What kind of drug therapy and for how long? When to operate? [Therapieresistente Refluxkrankheit : Wie und Wie Lange Medikamentös Therapieren? Wann Operieren?]

被引:0
作者
Labenz J. [1 ]
Feuner H. [2 ]
机构
[1] Medizinische Klinik, Ev. Jung-Stilling-Krankenhaus, Siegen 57074
[2] Chirurgische Klinik und Poliklinik, TU München, München
来源
Der Gastroenterologe | 2009年 / 4卷 / 5期
关键词
Fundoplication; Gastro-esophageal reflux disease; Lifestyle measures; Proton pump inhibitor; Therapy-resistant heartburn;
D O I
10.1007/s11377-009-0290-6
中图分类号
学科分类号
摘要
Gastro-esophageal reflux disease (GERD) is common. Standard treatment includes lifestyle measures and proton pump inhibitors (PPIs). GERD is considered to be refractory to treatment when a standard dose of PPI fails to sufficiently control symptoms within 8 weeks. Severe reflux esophagitis may require a longer period of treatment. In the event of therapy-resistant GERD, a stratified approach is needed if diagnostic errors and therapeutic confusion are to be avoided. Major stumbling blocks are misdiagnosis, inadequate acid suppression, and a pathophysiological situation in which acid plays only a minor role. When other potential esophageal or extra-esophageal causes have been excluded, the first step is to optimise acid inhibition measures. If problems nevertheless persist, a functional diagnostic workup is indicated, preferably using a combination of pH-metry and impedance monitoring. Depending on the outcome, the therapeutic options that are then most likely to be useful are intensification and optimisation of the antisecretory treatment, measures aimed at relaxing the lower esophageal sphincter, modulation of esophageal sensitivity, and surgical reconstruction of the gastro-esophageal antireflux barrier. © 2009 Springer Medizin Verlag.
引用
收藏
页码:393 / 402
页数:9
相关论文
共 39 条
[31]  
Nocon M., Labenz J., Willich S.N., Lifestyle factors and symptoms of gastro-oesophageal reflux a population-based study, Aliment Pharmacol Ther, 23, (2006)
[32]  
Rubenstein J.H., Nojkov B., Korsnes S., Et al., Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome, Aliment Pharmacol Ther, 26, (2007)
[33]  
Schey R., Parthasarathy D.R., Et al., Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease, Gastroenterology, 133, (2007)
[34]  
Sheu B.S., Chang W.L., Cheng H.C., Et al., Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole, Am J Gastroenterol, 103, (2008)
[35]  
Sharma N., Agrawal A., Freeman J., Et al., An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring, Clin Gastroenterol Hepatol, 6, (2008)
[36]  
Tack J., Koek G., Demedts I., Et al., Gastroesophageal reflux disease poorly responsive to singledose proton pump inhibitors in patients without Barrett's esophagus: Acid reflux, bile reflux, or both?, Am J Gastroenterol, 99, (2004)
[37]  
Teixeira J.P., Mosquera V., Flores A., Long-term outcomes of quality of life after laparoscopic Nissen fundoplication, Hepatogastroenterology, 56, (2009)
[38]  
Vakil N.V., Van Zanten S., Kahrilas P., Et al., The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus, Am J Gastroenterol, 101, (2006)
[39]  
Zerbib F., Duriez A., Roman S., Et al., Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors, Gut, 57, (2008)